Alfentanil: Simultaneous Testing Pilot
Status: | Completed |
---|---|
Conditions: | Gastrointestinal |
Therapuetic Areas: | Gastroenterology |
Healthy: | No |
Age Range: | 18 - 40 |
Updated: | 12/15/2017 |
Start Date: | October 2009 |
End Date: | September 2016 |
Novel Noninvasive Assessment of Cytochrome P4450 Activity: Simultaneous Testing Pilot
To evaluate two paradigms for simultaneous assessment of hepatic and intestinal CYP3A
activity.
activity.
Inclusion Criteria:
- Male or non-pregnant female, 18-40 yr. old
- Good general health with no remarkable medical conditions such as liver, kidney,
heart, or lung failure
- BMI between 20-33
- Provide informed consent
Exclusion Criteria:
- Known history of liver or kidney disease
- Use of prescription or non prescription medications, herbals or foods known to be
metabolized by or affect CYP3A (including oral birth control medications)
- Females who are pregnant or nursing
- Known history of drug or alcohol addiction (prior or present addiction or treatment
for addiction)
- Direct physical access to and routine handling of addicting drugs in the regular
course of duty (this is a routine exclusion from studies of drugs with addiction
potential).
- History of bradycardia
- Respiratory rate <10
- History of significant pulmonary disease
- History of pre-existing medical condition predisposing to respiratory depression
- Systolic blood pressure <100 mgHg and diastolic blood pressure <70mmHg
We found this trial at
1
site
Click here to add this to my saved trials